Risk factors
Immunic (IMUX) risk factors
Item 1A of every Immunic, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks10 new4 dropped8 reworded
Clinical trial execution and delays dominate risks. Nasdaq minimum bid price compliance threatens listing. Capital raises cause significant dilution.
Filed Feb 26, 2026 - FY2024 10-K risk factors72 risks
Clinical trials for lead candidate vidofludimus calcium were disrupted by Russia's invasion of Ukraine, forcing relocation from 60 sites. Auditor expressed going concern doubt due to ongoing losses and negative cash flows. Heavy reliance on clinical success of unproven drug candidates with no product sales revenue.
Filed Mar 31, 2025